Back to Search Start Over

The landscape of T-cell engagers for the treatment of follicular lymphoma

Authors :
Alfredo Rivas-Delgado
Ivan Landego
Lorenzo Falchi
Source :
OncoImmunology, Vol 13, Iss 1 (2024)
Publication Year :
2024
Publisher :
Taylor & Francis Group, 2024.

Abstract

Follicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, relies on interactions with immune elements in the tumor microenvironment, including T-follicular helper cells and follicular dendritic cells, for its survival and progression. Despite its initial responsiveness to chemoimmunotherapy, FL is generally considered incurable. Strategies to improve immune-mediated control of FL could significantly benefit this population, particularly as it includes many elderly and comorbid patients. Immune cell engagers, especially bispecific antibodies (BsAbs), are crucial in targeting FL by bridging tumor and effector cells, thereby triggering T-cell activation and cytotoxic killing. CD3 × CD20 BsAbs have shown the most promise in clinical development for B-NHL patients, with structural variations affecting their target affinity and potency. This review summarizes the current clinical trials of BsAbs for relapsed/refractory FL, highlighting the approval of some agents, their role in first-line treatment or combination therapies, their toxicity profiles, and the future of this therapeutic approach compared to other immune cell therapies.

Details

Language :
English
ISSN :
2162402X
Volume :
13
Issue :
1
Database :
Directory of Open Access Journals
Journal :
OncoImmunology
Publication Type :
Academic Journal
Accession number :
edsdoj.58a0910b16941e782316f10e9ee17bd
Document Type :
article
Full Text :
https://doi.org/10.1080/2162402X.2024.2412869